The company has revealed it added approximately $6m to a series A round co-led by AbbVie Ventures last year, bringing its total size to about $59m.

US-based immunotherapy developer Carisma Therapeutics has increased a series A round backed by pharmaceutical firms AbbVie and Merck & Co to approximately $59m, Philly has reported. Carisma had achieved a first $53m close for the round in June 2018 which was co-led by AbbVie’s corporate venturing unit, AbbVie Ventures, and venture capital firm HealthCap,…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.